Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 3/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.97 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.97 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.97 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.97 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | RHOC | P08134 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | THRB | P10828 | 1/20 | 0.83 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.83 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.83 |
| ▸ | PDE6D | O43924 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL137843 | 1.00 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL909379 | 1.00 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL27701543 | 0.99 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL27850403 | 0.99 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL137842 | 0.99 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL28456 | 0.99 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL41065 | 0.99 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL153886 | 0.99 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL28018746 | 0.98 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL3320399 | 0.98 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3654955-B1 | PHARMACEUTICAL COMPOSITIONS | LILLY CO ELI (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250009647-A1 | PHARMACEUTICAL COMPOSITION | MEDINCELL S.A. (FR) | 2025-01-09 | — | — | US | claimed |
| CN-115671077-B | Compound micropill capsule for preventing cardiovascular and cerebrovascular diseases and preparation method thereof | 乐普药业股份有限公司 | 2024-09-17 | — | — | CN | claimed |
| EP-4380546-A1 | PHARMACEUTICAL COMPOSITION | MedinCell S.A. (FR) | 2024-06-12 | — | — | EP | claimed |
| CN-118159252-A | Pharmaceutical composition | 美蒂森股份公司 | 2024-06-07 | — | — | CN | claimed |
| US-11918692-B2 | Pharmaceutical compositions | ELI LILLY AND COMPANY (US) | 2024-03-05 | — | — | US | claimed |
| EP-4188338-A1 | BILAYER TABLET COMPRISING EZETIMIBE AND ATORVASTATIN | KRKA, d.d., Novo mesto (SI) | 2023-06-07 | — | — | EP | claimed |
| CN-113230223-B | Preparation method of atorvastatin calcium film coated tablet | 宜昌人福药业有限责任公司 | 2023-04-07 | — | — | CN | claimed |
| WO-2023012357-A1 | PHARMACEUTICAL COMPOSITION | MEDINCELL (FR) | 2023-02-09 | — | — | WO | claimed |
| CN-115671077-A | Compound pellet capsule for preventing cardiovascular and cerebrovascular diseases and preparation method thereof | 乐普药业股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| WO-2019018158-A1 | PHARMACEUTICAL COMPOSITIONS | ELI LILLY AND COMPANY (US) | 2019-01-24 | — | — | WO | claimed |
| WO-2019010146-A1 | STATIN COMPOSITIONS AND METHODS FOR USE IN TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2019-01-10 | — | — | WO | claimed |
| EP-3340980-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND AN ECA INHIBITOR | Les Laboratoires Servier (FR) | 2018-07-04 | — | — | EP | claimed |
| CN-108135882-A | pharmaceutical composition comprising an HMG-CoA reductase inhibitor and an ACE inhibitor | 法国施维雅药厂 | 2018-06-08 | — | — | CN | claimed |
| CN-104127391-B | A kind of contain Atorvastatin calcium solid composite medicament | 李宝齐 | 2016-08-24 | — | — | CN | claimed |
| CN-104370794-B | Atorvastatin calcium compound | 天津汉瑞药业有限公司 | 2016-08-10 | — | — | CN | claimed |
| US-8933115-B2 | Stabilized statin formulations | CUMBERLAND PHARMACEUTICALS INC. (US) | 2015-01-13 | — | — | US | claimed |
| CN-102892287-B | Stabilized statin formulations | CUMBERLAND PHARMACEUTICALS INC | 2014-11-05 | — | — | CN | claimed |
| CN-104127391-A | Solid pharmaceutical composition containing atorvastatin calcium | LI BAOQI | 2014-11-05 | — | — | CN | claimed |
| WO-2009082362-A1 | A METHOD FOR PRODUCING STATINS IN PURE FORM | ULKAR KIMYA SAN. VE TIC. A.S. (TR) | 2009-07-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009647-A1 | PHARMACEUTICAL COMPOSITION | ADCY10, ADCY7, PDE10A | HMGCR 458/4885ABCB11 50/4885SLCO1B1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.